BRAF Mutated Non-small Cell Lung Cancer Market

DelveInsight's "BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC), historical and forecasted epidemiology as well as the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market report provides current treatment practices, emerging drugs, BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market share of the individual therapies, current and forecasted BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Disease Understanding and Treatment Algorithm

The DelveInsight’s BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market report gives a thorough understanding of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.

Lung cancer mainly begins in the lungs and may spread to lymph nodes or other organs in the body, such as the brain. However, cancer from other organs may also spread to the lungs. When cancer cells spread from one organ to another, they are called metastases.

There are mainly two types of lung cancer: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

NSCLC is the most common type of lung cancer, accounting for approximately 85% of all lung cancers. However, NSCLC metastasizes to other organs slower than SCLC, and microscopically, SCLC is composed of much smaller cells. If untreated, SCLC can be fatal in a few weeks, in contrast to most cases of NSCLC.

NSCLC can be defined as any epithelial lung cancer other than SCLC. It is mainly subcategorized into adenocarcinomas, squamous cell carcinomas, large cell carcinomas, and several other types that occur less frequently, including adenosquamous carcinomas and sarcomatoid carcinomas.

The symptoms of NSCLC and SCLC can be similar, including a persistent cough, chest pain, shortness of breath, wheezing, loss of appetite, weight loss, and unusual tiredness.

The diagnosis and staging of NSCLC are often done at the same time. The tests and procedures used to diagnose NSCLC are Physical Exam and History, Laboratory Tests, and Molecular Tests.

After lung cancer diagnosis, tests are done to determine if cancer cells have spread within the lungs or to other body parts. Finding cancer metastasis from the lungs to other body parts is known as staging, which is vital to planning the treatment method. There are IV stages of NSCLC.

Several BRAFs are expected to enter the NSCLC market; however, given the physicians’ familiarity with the existing products, we do not expect new entrants to disrupt the market significantly.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for BRAF Mutated Non-small Cell Lung Cancer (NSCLC).

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Treatment

It covers the details of conventional and current medical therapies available in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market for the treatment of the condition. It also provides BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment algorithms and guidelines in the United States, Europe, and Japan.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology 

The BRAF Mutated Non-small Cell Lung Cancer (NSCLC) epidemiology section provides insights about the historical and current BRAF Mutated Non-small Cell Lung Cancer (NSCLC) patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted BRAF Mutated Non-small Cell Lung Cancer (NSCLC) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

• The total number of NSCLC Incidence Cases of in the 7MM was nearly 526,800 in 2022 and is projected to increase during the forecasted period.
• The total number of incident cases of NSCLC in the United States was nearly 201,200 in 2022.
• The total number of cases in the United States for BRAF NSCLC was estimated to be nearly 10,000 in 2022, which is expected to show positive growth by 2034.
• The total number of cases in Japan for BRAF NSCLC was estimated to be nearly 2,500 in 2022, which is expected to show positive growth by 2034.
• Among EU4 and the UK, the highest number of cases for BRAF NSCLC was found in Germany, estimated to be nearly 2,000 cases in 2022, which is expected to show positive growth by 2034.

Country Wise- BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology

The epidemiology segment also provides the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Drug Chapters

The drug chapter segment of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) report encloses the detailed analysis of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) marketed drugs and late-stage (Phase-III and Phase-II) BRAF NSCLC Pipeline Drugs. It also helps to understand the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Marketed Drugs

The report provides the details of the marketed products/off-label treatments available for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Outlook

The BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market trends by analyzing the impact of current BRAF Mutated Non-small Cell Lung Cancer (NSCLC) therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

BRAF is a member of the RAF kinases that regulate the MAP kinase pathway; V600E is the most common mutation. Treatments for advanced NSCLC have evolved. Most patients have received 1L systemic chemotherapy followed by Immuno-oncology (IO) monotherapies, targeted therapies, and IO combination regimens.

Only one product is available for the BRAF-mutated NSCLC patient pool: TAFINLAR (dabrafenib) in combination with MEKINIST (trametinib). In June 2017, the US FDA approved TAFINLAR and MEKINIST to treat patients with metastatic NSCLC whose tumors express the BRAF V600E mutation. In April 2017, the European Commission approved TAFINLAR + MEKINIST for treating patients with BRAF V600-positive advanced or metastatic NSCLC. Additionally, in March 2018, TAFINLAR + MEKINIST was approved in Japan for treating unresectable advanced or recurrent NSCLC with BRAF mutations.

In 2022, the total market size of BRAF NSCLC by therapies in EU4 and the UK was approximately USD 250 million, which is expected to increase by 2034.

ZELBORAF (vemurafenib) is a treatment option for BRAFV600-mutated NSCLC patients when the dabrafenib/trametinib combination is not feasible or not reimbursed.

In 2022, TAFINLAR (dabrafenib) + MEKINIST (trametinib) captured the highest market size of BRAF NSCLC by therapies in Japan.

According to DelveInsight, the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market in 7MM is expected to witness a major change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market in 7MM.

The United States BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Outlook

This section provides the total BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market size and market size by therapies in the United States.

EU-5 Countries: BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Outlook

The total BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Outlook

The total BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market size and market size by therapies in Japan is also mentioned.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Drugs Uptake

This section focuses on the rate of uptake of the potential BRAF Mutated Non-small Cell Lung Cancer (NSCLC) drugs recently launched in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market or expected to get launched in the market during the study period 2020-2034. The analysis covers BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market uptake by drugs; patient uptake by therapies; and sales of each drug.   

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Pipeline Development Activities

The BRAF Mutated Non-small Cell Lung Cancer (NSCLC) report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses BRAF Mutated Non-small Cell Lung Cancer (NSCLC) key players involved in developing targeted therapeutics.

Pipeline Development Activities

The BRAF Mutated Non-small Cell Lung Cancer (NSCLC) report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) emerging therapies.

Reimbursement Scenario in BRAF Mutated Non-small Cell Lung Cancer (NSCLC)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market trends, we take KOLs and SMEs ' opinion working in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Report

• The report covers the descriptive overview of BRAF Mutated Non-small Cell Lung Cancer (NSCLC), explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Report Highlights

• In the coming years, the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence BRAF Mutated Non-small Cell Lung Cancer (NSCLC) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major players are involved in developing therapies for BRAF Mutated Non-small Cell Lung Cancer (NSCLC). The launch of emerging therapies will significantly impact the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for BRAF Mutated Non-small Cell Lung Cancer (NSCLC)
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Report Insights

• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Patient Population
• Therapeutic Approaches
• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Pipeline Analysis
• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Size and Trends
• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Opportunities
• Impact of upcoming BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Therapies

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Report Key Strengths

• 10 Years Forecast
• 7MM Coverage
• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed BRAF Mutated Non-small Cell Lung Cancer Market
• BRAF Mutated Non-small Cell Lung Cancer Drugs Uptake

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Report Assessment

• Current Treatment Practices
• Unmet Needs
• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Pipeline Product Profiles
• BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Attractiveness
• BRAF Mutated Non-small Cell Lung Cancer Market Drivers
• BRAF Mutated Non-small Cell Lung Cancer Market Barriers

Key Questions

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Market Insights:

• What was the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) drug class share (%) distribution in 2024 and how it would look like in 2034?
• What would be the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market size during the forecast period (2024-2034)?
• At what CAGR, the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market is expected to grow by 7MM during the forecast period (2024-2034)?
• What would be the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market outlook across the 7MM during the forecast period (2024-2034)?
• What would be the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

BRAF Mutated Non-small Cell Lung Cancer (NSCLC) Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of the BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
• What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical BRAF Mutated Non-small Cell Lung Cancer (NSCLC) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
• Out of all 7MM countries, which country would have the highest prevalent population of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) during the forecast period (2024-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2024-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of BRAF Mutated Non-small Cell Lung Cancer (NSCLC) in the USA, Europe, and Japan?
• What are the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
• How many therapies are in-development by each company for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment?
• How many are emerging therapies in mid-stage, and late stage of development for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?
• What are the global historical and forecasted market of BRAF Mutated Non-small Cell Lung Cancer (NSCLC)?

Reasons to buy

• The report will help in developing business strategies by understanding trends shaping and driving the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market
• To understand the future market competition in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market
• To understand the future market competition in the BRAF Mutated Non-small Cell Lung Cancer (NSCLC) market

Stay Updated with us for Recent Articles

• The Next Chapter in NSCLC Treatment Space: Recent Discoveries and Innovations
• Novel mutation-targeting therapies in the horizon to relieve the global healthcare burden NSCLC poses
• Non-Small Cell Lung Cancer Market: Treatments and Market Forecast
• Evaluating Key Advancements and Emerging Therapies in EGFR-Non Small Cell Lung Cancer Treatment Market
• Novel Insights Into The Non-Small Cell Lung Cancer Market
• Evolving Landscape for Rare Biomarkers in Non-Small Cell Lung Cancer
• Latest DelveInsight Blogs

Related Infographics of the Report

• BRAF Non-Small Cell Lung Cancer (BRAF+ NSCLC) Market
• ALK Non-Small Cell Lung Cancer (ALK+ NSCLC) Market
• c-MET Non-Small Cell Lung Cancer (c-MET+ NSCLC) Market
• EGFR Non-Small Cell Lung Cancer (EGFR+ NSCLC) Market
• PD-L1Non-Small Cell Lung Cancer (PD-L1+ NSCLC) Market